Alzheimer's, Novo Nordisk
Digest more
While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, both in growth and pipeline progression.
Novo Nordisk shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.
Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results